Neueste Versuche

EudraCT Number: 2010-024094-39

Sponsor Protocol Number: Adip-2010

Start Date:

Sponsor Name: University of Ulm, University Hospital Ulm

Full Title: Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten.

Medical condition: The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP. Subjects are ...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2005-003023-40

Sponsor Protocol Number: 21805

Start Date:

Sponsor Name: Food Standards Agency

Full Title: The role of peanut specific T cell responses in children with peanut allergy and in children who are tolerant to peanuts

Medical condition: Children with Peanut Allergy

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2020-005019-29

Sponsor Protocol Number: Rux-cALL-Pol_2020

Start Date:

Sponsor Name: Medical University of Lodz

Full Title: Single-arm interventional study with ruxolitinib and AIOEP-BFM2017 chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.

Medical condition: Acute Lymphoblastic Leukemia with confirmed activating of JAK/STAT pathway in children and adolescents

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10000845	Acute lymphoblastic leukemia	LLT
	22.0	100000004850	10072213	JAK-2 mutation	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2007-000730-40

Sponsor Protocol Number: SOCRATES

Start Date:

Sponsor Name: Heinrich-Heine-Universität Düsseldorf

Full Title: Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC)

Medical condition: histologically proven advanced hepatocellular carcinoma (HCC) not suitable for resection or liver transplantation but without extrahepatic manifestations and without previous treatment for HCC

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10019828	Hepatocellular carcinoma non-resectable	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2009-011148-21

Sponsor Protocol Number: D0520C00012

Start Date:

Sponsor Name: AstraZeneca AB

Full Title: A 12-week, randomised, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 do...

Medical condition: Chronic Obstructive Pulmonary Disease (COPD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10010952	COPD	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) SK (Completed)

Trial results: View results

EudraCT Number: 2004-001316-31

Sponsor Protocol Number: E01/04/SLIT1-M

Start Date:

Sponsor Name: ALK-ABELLO, S.A.

Full Title: TOLERABILIDAD DE LAS VACUNAS ALERGÉNICAS VALORADAS EN UNIDADES DE MASA Y ADMINISTRADAS POR VÍA SUBLINGUAL. ESTUDIO RANDOMIZADO DOBLE CIEGO CONTROLADO CON PLACEBO EN PACIENTES CON ENFERMEDAD ALÉRGIC...

Medical condition: Rinitis o rinoconjuntivitis alérgica perenne (ácaros) o estacional (gramíneas) con/sin síntomas de asma

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: View results

EudraCT Number: 2009-011911-19

Sponsor Protocol Number: QUE/09

Start Date:

Sponsor Name: Ludwig-Maximilian-University of Munich, Department of Psychiatry

Full Title: Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients

Medical condition: In this study, patients suffering from unipolar depression are investigated. 40 unipolar depressed inpatients (age 18-65) enter the study after the procedure has been fully explained and written in...

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10012378	Depression	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-000761-16

Sponsor Protocol Number: ALXN1210-TMA-314

Start Date:

Sponsor Name: Alexion Pharmaceuticals, Inc.

Full Title: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to

Medical condition: hematopoietic stem cell transplant-associated thrombotic microangiopathy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10005329 - Blood and lymphatic system disorders	10043645	Thrombotic microangiopathy	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-004194-51

Sponsor Protocol Number: 020520

Start Date:

Sponsor Name: Medical University of Lodz

Full Title: A prospective, randomized, phase III open-label clinical trial with blinded end-point assessment to evaluate the efficacy and safety of cyclosporine and methotrexate in children and adolescent subj...

Medical condition: Atopic dermatitis

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-005092-13

Sponsor Protocol Number: MO42623

Start Date:

Sponsor Name: F. Hoffmann-La Roche Ltd

Full Title: A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED ≥ 13 AND

Medical condition: Severe or Moderate Hemophilia A

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10053753	Hemophilia A without inhibitors	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Prematurely Ended) DE (Ongoing) ES (Ongoing) IT (Ongoing) HU (Ongoing)

Trial results: (No results available)

Neueste Versuche

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen